Please login to the form below
renal cell carcinoma
This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
of health-related quality of life in a phase 3 trial in first-line renal cell carcinoma (RCC) – the most common form of kidney cancer. ... We continue to see an increasing number of patients diagnosed with advanced renal cell carcinoma and remain
Latest news
-
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales
plus Merck &Co’s checkpoint inhibitor Keytruda for the first-line treatment of advanced renal cell carcinoma (RCC).
-
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma. ... The European Commission (EC) has approved a combination of Bristol Myers Squibb’s (BMS) Opdivo with Ipsen’s Cabometyx for
-
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
New data for Merck &Co (MSD) and Eisai’s Keytruda plus Lenvima combination treatment has demonstrated further promise for the therapy in advanced renal cell carcinoma (RCC) – the most common form ... If approved, we believe this combination has the
-
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
sunitinib) in the first-line treatment of advanced renal cell carcinoma (RCC) – the most common type of kidney cancer in adults. ... This regimen brings together two proven agents in advanced renal cell carcinoma, and we believe it will play an
-
BMS gains FDA approval for second Opdivo combo in kidney cancer
BMS' Opdivo/Yervoy regimen was its first combo to be approved for advanced renal cell carcinoma. ... The US Food and Drug Administration (FDA) has approved a combination of Bristol Myers Squibb’s (BMS) Opdivo with Exelixis’ Cabometyx in renal cell
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales
European Commission approves Opdivo plus Cambometyx for advanced kidney cancer
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer
More from news
Approximately 14 fully matching, plus 153 partially matching documents found.
Latest Intelligence
-
The handover: Pfizer reshapes itself for a new era
The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent. ... Pfizer also has a considerable stake in
-
Charting a course for expansion
Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease
-
Deal Watch March 2016
Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
-
Deal Watch December 2015
510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.
-
Pharma deals during April 2014
Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and
The handover: Pfizer reshapes itself for a new era
Charting a course for expansion
Deal Watch March 2016
Pharma deals during April 2014
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
New hires at Crescendo, Healx and Galecto
oncology. Prior to Crescendo, Hashimoto (pictured below, right) led the clinical development of a checkpoint inhibitor in renal cell carcinoma at Roche, and held responsibility for multiple. ... This experience will be crucial as we progress our pipeline
-
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”.
-
CytomX appoints Rachel Humphrey chief medical officer
Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.
-
Former Bayer oncology head Robert Rosen joins AP Pharma's board
While at Bayer Rosen led launch of Nexavar for renal cell carcinoma and hepatocellular carcinoma. ... Rosen was in charge of Bayer's oncology efforts from 2005 to 2011, where he led the launch of Nexavar (sorafenib) for the treatment of renal cell
New hires at Crescendo, Healx and Galecto
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
-
Therapy Watch expands its oncology portfolio
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Cell Carcinoma.
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate
-
A stumble, but not a fall – what’s next for Opdivo?
and renal cell carcinoma (kidney cancer). ... Back then, the UK’s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital project manager
-
Competitive
-
Digital account director
-
Competitive
-
Digital strategist
-
Competitive
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Events Executive
-
Depending on Experience
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- EU approves bluebird bio’s CALD gene therapy Skysona
- Employee wellbeing in creative agencies: three tips to get you started
- High demand for innovative digital healthcare communication services leads to the continued growth of specialist agency, AMICULUM® Digital
- Managing unhelpful pressure in your creative agency: the human approach
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
- J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- Take part in research with Oxford University Press (OUP)
- Medical affairs - the time for change is now
PMHub
Onyx Health Ltd
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
- #DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
- In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
